1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD38

CD38

CD38 is a glycoprotein found on the surface of many immune cells, including T cells, B cells and natural killer cells. Additionally, CD38 has been shown to be a bifunctional enzyme expressing both ADP-ribosyl cyclase and cADPR hydrolase activities. The role of CD38 in immune cells ranges from modulating cell differentiation to effector functions during inflammation, where CD38 may regulate cell recruitment, cytokine release, and NAD availability. In line with a role in inflammation, CD38 appears to also play a critical role in inflammatory processes during autoimmunity. Because of CD38 expression is highly upregulated on human plasma cells and especially on multiple myeloma cells.Targeting of CD38 is one of the most important and promising treatment avenues to help patients suffering from multiple myeloma.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-123999
    CD38 inhibitor 1
    99.83%
    CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38.
    CD38 inhibitor 1
  • HY-P9915
    Daratumumab
    98.90%
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
    Daratumumab
  • HY-N0640
    Kuromanin chloride
    Inhibitor 99.50%
    Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities.
    Kuromanin chloride
  • HY-150508
    MK-0159
    Inhibitor 99.72%
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
    MK-0159
  • HY-144987
    RBN013209
    98.87%
    RBN013209 is a potent CD38 inhibitor with an IC50 of 0.01-0.1 μM for human CD38. RBN013209 can be used for the research of of cancer.
    RBN013209
  • HY-P9976A
    Isatuximab (anti-CD38)
    98.44%
    Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC).
    Isatuximab (anti-CD38)
  • HY-156120
    CD38 inhibitor 3
    Inhibitor
    CD38 inhibitor 3 (compound 1) is a potent CD38 inhibitor (IC50=11 nM). CD38 inhibitor 3 can promote mitochondrial biogenesis, reduce lactate levels, and increase NAD+ content and Nrf2 expression. In a model of mitochondrial myopathy, CD38 inhibitor 3 increases muscle contraction/development and improves exercise tolerance in Pus1-/- mice.
    CD38 inhibitor 3
  • HY-P990037
    Erzotabart
    Inhibitor
    Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity.
    Erzotabart
  • HY-P9915A
    Daratumumab (PBS)
    Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
    Daratumumab (PBS)
  • HY-P99616
    Felzartamab
    Inhibitor 99.34%
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research.
    Felzartamab
  • HY-134358A
    Ara-F-NAD+ sodium
    Inhibitor
    Ara-F-NAD+ sodium is an arabino analogue of NAD+. Ara-F-NAD+ sodium is a potent, reversible and slow-binding CD38 NADase inhibitor.
    Ara-F-NAD+ sodium
  • HY-P99730
    Mezagitamab
    Inhibitor
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
    Mezagitamab
  • HY-129997
    Luteolinidin chloride
    99.14%
    Luteolinidin is a natural deoxyanthocyanidin, isolated from Sorghum bicolor . Luteolinidin is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.
    Luteolinidin chloride
  • HY-144988
    CD38 inhibitor 2
    98.81%
    CD38 inhibitor 2 is a potent CD38 inhibitor (IC50 = 0.01 ~ 0.1 μΜ).
    CD38 inhibitor 2
  • HY-P99744
    Modakafusp alfa
    Inhibitor
    Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules. Modakafusp alfa can be used in the research of multiple myeloma.
    Modakafusp alfa
  • HY-134358
    Ara-F-NAD+
    Inhibitor
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor.
    Ara-F-NAD+
  • HY-119648A
    (E/Z)-CCR-11
    Inhibitor 98.00%
    (E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.
    (E/Z)-CCR-11
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity